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Opening	  QuesIons	  to	  ICB	  II	  
• Will	  ICB	  meet	  are	  future	  needs?	  
• How	  good	  does	  it	  need	  to	  be?	  
•  Are	  we	  at	  a	  9pping	  point?	  
•  Is	  ICB	  game	  changing	  in	  
pharmaceu9cal	  manufacturing?	  
• Where	  do	  we	  want	  to	  go,	  why	  
and	  how?	  
Integrated	  ConInuous	  Bioprocessing	  
a	  star&ng	  point	  
•  We	  are	  here	  as	  believers	  in	  ICB	  but	  we	  need	  to	  
understand	  why	  we	  should	  invest	  
•  We	  all	  have	  similar	  and	  different	  reasons	  to	  pursue	  ICB	  
•  We	  all	  bring	  a	  disability	  to	  the	  table	  
•  The	  number	  of	  symposia	  aAests	  to	  expanding	  interest,	  
BUT	  how	  will	  that	  translate	  to	  ac9on?	  
•  As	  I	  have	  listened	  to	  the	  presenta9ons	  and	  discussion	  
in	  the	  hallway,	  what	  have	  I	  heard?	  
•  I	  will	  try	  to	  place	  ICB	  into	  context	  with	  the	  issues	  in	  the	  
industry	  and	  the	  needs	  of	  the	  firms	  
The	  GOAL	  of	  pharmaceu9cal	  
manufacturing	  is	  the	  sustained	  
delivery	  of	  a	  quality	  product	  (safe	  
and	  efficacious)	  to	  the	  paIent	  
Technology	  provides	  the	  tools	  
that	  can	  tacIcally	  be	  deployed	  
to	  help	  us	  get	  there	  (cost,	  
producIvity,	  quality,	  etc.)	  
Emerging	  Issues	  in	  PharmaceuIcal	  
Industry	  
•  Diverse	  porJolio	  of	  biological	  products	  
•  Uncertain	  regulatory	  outcome	  on	  novel	  therapies	  
•  Expanding	  markets	  with	  demand	  uncertainty	  
– New	  and	  small	  indica9ons	  –	  Precision	  Medicine	  
– New	  and	  large	  indica9ons	  –	  Access	  to	  Medicine	  
•  Redefining	  the	  blockbuster	  drug	  
•  Changing	  structure	  of	  the	  industry	  	  
•  Tension	  on	  pricing	  and	  capital	  constraints	  
Issues	  drive	  opportunity	  while	  barriers	  constrain	  it	  
Historical	  PerspecIve	  to	  Meet	  Product	  
Demand	  –	  Industrial	  Evolu&on	  





•  Driven	  by	  need	  to	  	  
–  Reduce	  cost	  
– Meet	  market	  demand	  
– Decentralize	  manufacturing	  
– Assure	  robust	  quality	  




ConInuous	  Biomanufacturing	  is	  
Not	  New	  
•  Con9nuous	  culture	  –	  1950’s	  
•  Con9nuous	  extrac9on	  of	  penicillin	  1950’s	  
•  Con9nuous	  chromatography	  1950-­‐60’s	  
•  Fed-­‐batch	  &	  repeated	  withdrawal	  for	  
penicillin	  produc9on	  (aka	  Perfusion)	  1960’s	  
•  Tangen9al	  flow	  filtra9on	  1960’s	  
•  Con9nuous	  crystalliza9on	  for	  AA’s	  –	  1960’s	  
•  Con9nuous	  brewing	  from	  the	  1890’s	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Batch Manufacturing is by Choice 
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Through	  an	  Upstream	  Process	  Lens	  
•  Upstream	  Process	  
–  Robust	  product	  quality	  thru	  9ghter	  control	  of	  
chemistry	  and	  9me	  in	  perfusion	  culture	  
– High	  cell	  density	  and	  produc9vity	  =	  lower	  CapX	  &	  OpX	  
–  Single	  use	  technology	  
–  Low	  cost	  media	  ßà	  Perfusion	  Culture	  
–  Pipeline	  (expanded,	  diverse,	  uncertain)	  requires	  
flexibility	  in	  technology	  and	  facility	  
–  The	  Biogen	  Challenge:	  get	  4X	  capacity	  from	  plaJorm	  
What	  I	  heard	  this	  week	  
Through	  a	  Downstream	  Process	  Lens	  
•  Downstream	  Process	  
–  Reten9on	  system	  is	  the	  interface	  -­‐	  flexibility	  
–  Retain	  the	  DSP	  architecture	  and	  convert	  to	  flow	  through	  and	  
no	  pooling	  
•  Mul9column	  chromatography	  opens	  up	  capacity	  
•  SPTFF	  	  
•  Con9nuous	  viral	  inac9va9on	  
–  Consider	  alterna9ves:	  Precipita9on,	  Extrac9on,	  Crystalliza9on	  
–  Func4onally	  closed	  systems	  
–  Single	  use	  technology	  
–  Control	  of	  fluid	  management	  
–  In-­‐line	  and	  at-­‐line	  sensors	  and	  automa9on	  
What	  I	  heard	  this	  week	  
Through	  a	  business	  lens	  
•  Flexibility/Agility	  to	  meet	  uncertain	  demand	  
– New	  diverse	  products	  
– New	  markets	  	  	  
•  Cost	  effec9ve	  ability	  to	  meet	  future	  needs	  
•  Op9mize	  present	  &	  future	  capability	  and	  capacity	  
•  Improving	  Speed	  to	  Clinic	  and	  Market	  
•  Real	  9me	  assurance	  of	  Product	  Quality	  
•  Regulatory	  clarity	  
•  Dominant	  design	  &	  standards	  in	  the	  ICB	  toolkit	  
What	  I	  heard	  this	  week	  
Through	  a	  Regulatory	  Lens	  
•  First	  approval	  of	  product	  by	  con9nuous	  manufacturing	  
•  ICB	  as	  an	  “evolu9on	  not	  a	  revolu9on”	  
•  15	  years	  of	  Ini9a9ves	  to	  improve	  &	  clarify	  approval	  
–  QbD	  and	  PAT	  enable	  and	  support	  transi9on	  to	  ICB	  
•  Goal	  to	  align	  field	  opera9ons	  with	  the	  Center	  
•  Seek	  interna9onal	  collabora9on	  on	  harmoniza9on	  
•  Establishment	  of	  the	  Office	  of	  Product	  Quality	  
•  Recogni9on	  of	  enabling	  new	  technology	  
–  Emerging	  Technology	  Team	  
–  Encouragement	  of	  precompe99ve	  collabora9on	  
–  Challenges	  to	  tradi9onal	  regula9on	  by	  RTR,	  QMS,	  automa9on,	  
scaling	  in	  9me,	  etc.	  	  
What	  I	  heard	  this	  week	  
Why	  is	  ICB	  emerging	  now?	  
EvoluIon	  in	  Technology	  
•  Cell	  reten9on	  
•  Cellular	  produc9vity	  
•  Media	  development	  
•  MAB	  plaJorm	  
•  Mul9column	  Chrom.	  
•  SPTFF	  
•  Single	  Use	  Technology	  
•  Analy9cs	  and	  Automa9on	  
•  Closed	  systems	  
Emerging	  Business	  Case	  
•  Enabling	  
•  Specialized	  &	  Potent	  
molecules	  
•  Reduce	  cost	  
•  Enhance	  supply	  
•  Improve	  produc9vity	  
•  Assure	  quality	  
•  Increase	  flexibility	  
•  Addressing	  the	  Pharma	  
Industry	  issues	  	  
What	  I	  heard	  this	  week	  
Barriers	  &	  Challenges	  	  
•  Regulatory	  uncertainty	  	  
–  LiAle	  experience	  with	  innova9ve	  technologies	  
–  Percep9on	  of	  regulatory	  constraints	  (self	  inflicted	  
wounds)	  
•  Market	  uncertainty	  for	  new	  products	  
•  Complex	  product	  and	  thus	  process	  porJolios	  	  
•  Geographically	  diverse	  markets	  
•  Lack	  of	  experience	  with	  new	  technologies	  
•  Managing	  breakthrough	  and	  orphan	  designa9on	  
•  Organiza9on	  –	  development,	  opera9on	  and	  
quality	  	  
What	  I	  heard	  this	  week	  
How	  are	  we	  doing?	  
ImplicaIons	  of	  ICB	  
Are	  we	  ready?	  
•  Opera9ng	  in	  a	  new	  ecosystem	  
– New	  dependencies	  on	  materials,	  suppliers	  and	  
collaborators	  
–  Closer	  rela9onship	  with	  regulators	  
•  Flexibility	  to	  address	  uncertainty	  in	  markets,	  
products,	  technology	  –	  are	  the	  physical	  and	  
human	  assets	  in	  place?	  
•  Is	  your	  QMS	  appropriate	  and	  enabled?	  
•  Do	  you	  have	  a	  culture	  recep9ve	  to	  innova9on	  
and	  change	  with	  an	  appe9te	  for	  risk?	  
•  Can	  you	  translate	  con9nuous	  units	  to	  processes?	  
•  U9liza9on	  of	  legacy	  assets?	  
Call	  to	  AcIon!	  
•  The	  goal	  is	  about	  Supply	  and	  Quality	  
–  Central	  to	  dispersed	  supply	  chains	  
– Analy9cal	  support	  of	  quality	  
•  Process	  intensifica9on	  is	  a	  strategy	  and	  tac9cs	  
are	  technology	  
•  Improve	  current	  (incremental),	  develop	  new	  
(radical)	  and	  employ	  hybrid	  processes	  
•  Collabora9on	  to	  sustain	  innova9on	  
•  Remove	  USP	  and	  DSP	  from	  vocabulary	  -­‐	  	  it	  is	  ICB	  
•  Break	  down	  tradi9onal	  interfaces:	  physical,	  
organiza9onal,	  disciplinary	  
How	  are	  we	  doing?	  
•  Excited	  by	  what	  is	  being	  accomplished	  
•  Fearful	  that	  it	  will	  take	  too	  long	  
•  Saddened	  that	  it	  has	  taken	  so	  long	  
